Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

US-FDA Approved Drugs in 2020 and 2021: A Review

Author(s): Indu Passi, Sushant Salwan and Bhupinder Kumar*

Volume 23, Issue 12, 2023

Published on: 29 December, 2022

Page: [1273 - 1297] Pages: 25

DOI: 10.2174/1389557523666221208104530

Price: $65

Abstract

Introduction: Throughout the years, the disruption caused by COVID-19 continues to pose an excess of challenges for the pharmaceutical industry. Throughout the entire year, questions were raised that does COVID-19 have a negative impact on new drug approvals. However, the answer to those questions was a ‘big no’.

Methods: We propose a compilation and analysis of around 100 medications, including small new molecular entities (NMEs), approved by the US Food and Drug Administration for the years 2020 and 2021. Novel drug discovery is crucial for pharmaceutical research and development as well as patient care. The only possible way to achieve this crucial goal is to repurpose current medications that may have anticipated effects as possible candidates. The availability of new drugs and biological products often means new treatment options for patients and advances in health care.

Results: Around 40% of the drugs were approved for various types of cancers. Other major therapeutic areas that were focused on were neurological products (around 17%), infectious diseases (13-15%), and cardiovascular disorders (7-8%). Various new products were approved for rare diseases (58-60%). This study aimed to discover a pattern in FDA medicine approvals during the last two decades.

Conclusion: This data shows that anticancer medicines and biologics are receiving increased attention in research. With a bigger number of biologically derived medications being produced, the price could rise much higher. FDA should embrace innovative techniques that will stimulate the industry to enhance research and development of novel compounds or medications that can deliver considerable improvements over existing ones. To put it briefly, FDA had to update our approach to regulation as a whole in order to effectively develop the types of technologies that are becoming available. Modernizing medical product review programmes is a part of this. These initiatives are part of the Medical Innovation Access Plan.

Keywords: USFDA, CDER, COVID-19, new molecular entities (NME’s), monoclonal antibody, GIST.

« Previous Next »
Graphical Abstract

[1]
Urquhart, L. FDA new drug approvals in Q1 2020. Nat. Rev. Drug Discov., 2020, 19(5), 299-300.
[http://dx.doi.org/10.1038/d41573-020-00074-4] [PMID: 32296148]
[2]
de la Torre, B.G.; Albericio, F. The pharmaceutical industry in 2020. An analysis of FDA drug approvals from the perspective of molecules. Molecules, 2021, 26(3), 627.
[http://dx.doi.org/10.3390/molecules26030627] [PMID: 33504104]
[3]
Urquhart, L. FDA new drug approvals in Q2 2020. Nat. Rev. Drug Discov., 2020, 19(8), 503-504.
[http://dx.doi.org/10.1038/d41573-020-00129-6] [PMID: 32651466]
[4]
Bhutani, P.; Joshi, G.; Raja, N.; Bachhav, N.; Rajanna, P.K.; Bhutani, H.; Paul, A.T.; Kumar, R. FDA approved drugs from 2015–June 2020: A perspective. J. Med. Chem., 2021, 64(5), 2339-2381.
[http://dx.doi.org/10.1021/acs.jmedchem.0c01786] [PMID: 33617716]
[5]
Urquhart, L. FDA new drug approvals in Q3 2020. Nat. Rev. Drug Discov., 2020, 19(11), 746-747.
[http://dx.doi.org/10.1038/d41573-020-00182-1] [PMID: 33046853]
[6]
WHO report on cancer: Setting priorities, investing wisely and providing care for all. 2020. Available from: https://www.who.int/publications/i/item/9789240001299
[7]
Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol. Res., 2020, 152, 104609.
[http://dx.doi.org/10.1016/j.phrs.2019.104609]
[8]
Priyadharsini, R. Novel anticancer drugs approved in 2020. BioMed. R J., 2021, 5(3), 475-479.
[9]
Reeta, K.H.; Sarangi, S.C.; Sopory, P.; Pattnaik, S.S. Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management. Indian J. Pharmacol., 2020, 52(5), 402-413.
[http://dx.doi.org/10.4103/ijp.IJP_475_18] [PMID: 33283772]
[10]
Sood, N.; Simon, P.; Ebner, P.; Eichner, D.; Reynolds, J.; Bendavid, E.; Bhattacharya, J. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. JAMA, 2020, 323(23), 2425-2427.
[http://dx.doi.org/10.1001/jama.2020.8279] [PMID: 32421144]
[11]
Kandimalla, R.; John, A.; Abburi, C.; Vallamkondu, J.; Reddy, P.H. Current status of multiple drug molecules, and vaccines: An update in SARS-CoV-2 therapeutics. Mol. Neurobiol., 2020, 57(10), 4106-4116.
[http://dx.doi.org/10.1007/s12035-020-02022-0] [PMID: 32671688]
[12]
Yüce, M.; Filiztekin, E.; Özkaya, K.G. COVID-19 diagnosis A review of current methods. Biosens. Bioelectron., 2021, 172, 112752.
[http://dx.doi.org/10.1016/j.bios.2020.112752] [PMID: 33126180]
[13]
Jahangir, M.A.; Muheem, A.; Rizvi, M.F. Coronavirus (COVID-19): History, current knowledge and pipeline medications. Int. J. Pharm. Pharmacol., 2020, 4(1), 1-9.
[http://dx.doi.org/10.31531/2581-3080.1000153]
[14]
Tripathi, R.; Alqahtani, S.S.; Albarraq, A.A.; Meraya, A.M.; Tripathi, P.; Banji, D.; Alshahrani, S.; Ahsan, W.; Alnakhli, F.M. Awareness and preparedness of COVID-19 outbreak among healthcare workers and other residents of South-West Saudi Arabia: A cross-sectional survey. Front. Public Health, 2020, 8, 482.
[http://dx.doi.org/10.3389/fpubh.2020.00482] [PMID: 33014977]
[15]
Saha, A.; Sharma, A.R.; Bhattacharya, M.; Sharma, G.; Lee, S.S.; Chakraborty, C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more. Arch. Med. Res., 2020, 51(6), 585-586.
[http://dx.doi.org/10.1016/j.arcmed.2020.05.001] [PMID: 32439198]
[16]
Walters, M. Avapritinib (AYVAKIT, Blueprint Medicines)–all entries with PAPs. Available from: https://www.hoparx.org/drug-updates-from-the-fda/ayvakit-avapritinib (Accessed on: 27/01/2022).
[17]
Dhillon, S. Avapritinib: First approval. Drugs, 2020, 80(4), 433-439.
[http://dx.doi.org/10.1007/s40265-020-01275-2] [PMID: 32100250]
[18]
Markham, A. Teprotumumab: First approval. Drugs, 2020, 80(5), 509-512.
[http://dx.doi.org/10.1007/s40265-020-01287-y] [PMID: 32157641]
[19]
Ali, F.; Chorsiya, A.; Anjum, V.; Ali, A. Teprotumumab (Tepezza): From the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. In: Int. Opthalmol; , 2021; p. 1-13.
[20]
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes. 2020. Available from: https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzatm-teprotumumab-trbw-significantly-reduces-proptosis-eye (Accessed on: 27/01/2022).
[21]
Fala, L. Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma. Payers Guide, 2020, 13, 3053.
[22]
Hoy, S.M. Tazemetostat: First approval. Drugs, 2020, 80(5), 513-521.
[http://dx.doi.org/10.1007/s40265-020-01288-x] [PMID: 32166598]
[23]
Salles, G. Highlights in relapsed/refractory follicular lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: Commentary. Clin. Adv. Hematol. Oncol., 2021, 19(1)(Suppl. 2), 13-16.
[PMID: 33843858]
[24]
Markham, A. Bempedoic acid: First approval. Drugs, 2020, 80(7), 747-753.
[http://dx.doi.org/10.1007/s40265-020-01308-w] [PMID: 32314225]
[25]
Elliott, W.; Chan, J. Bempedoic acid (Nexletol)/bempedoic acid and ezetimibe (Nexlizet). Intern. Med. Alert., 2020, 42(6)
[26]
Dhillon, S. Eptinezumab: First approval. Drugs, 2020, 80(7), 733-739.
[http://dx.doi.org/10.1007/s40265-020-01300-4] [PMID: 32266704]
[27]
Lenzner, P.H.O.J. H. Lundbeck A/S: Lundbeck announces European Medicines Agency acceptance of marketing authorization application for eptinezumab for the prevention of migraine.
[28]
Kang, C.; Shirley, M. Amisulpride: A review in post-operative nausea and vomiting. Drugs, 2021, 81(3), 367-375.
[http://dx.doi.org/10.1007/s40265-020-01462-1] [PMID: 33656662]
[29]
de Vries, T.; Al-Hassany, L. MaassenVanDenBrink, A. Evaluating rimegepant for the treatment of migraine. Expert Opin. Pharmacother., 2021, 22(8), 1-7.
[30]
Scott, L.J. Rimegepant: First approval. Drugs, 2020, 80(7), 741-746.
[http://dx.doi.org/10.1007/s40265-020-01301-3] [PMID: 32270407]
[31]
Frampton, J.E. Isatuximab: A review of its use in multiple myeloma. Target. Oncol., 2021, 16(5), 675-686.
[http://dx.doi.org/10.1007/s11523-021-00827-0] [PMID: 34351561]
[32]
Delgado, J.; Zienowicz, M.; Hennik, P.B.; Moreau, A.; Gisselbrecht, C.; Enzmann, H.; Pignatti, F. EMA review of isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma. Oncologist, 2021, 26(11), 983-987.
[http://dx.doi.org/10.1002/onco.13892] [PMID: 34213061]
[33]
Duggan, S. Osilodrostat: First approval. Drugs, 2020, 80(5), 495-500.
[http://dx.doi.org/10.1007/s40265-020-01277-0] [PMID: 32141023]
[34]
Elliott, W.; Chan, J. Osilodrostat tablets (Isturisa). Inter. Med. Alert., 2020, 42(8), 1.
[35]
Pivonello, R.; Fleseriu, M.; Newell-Price, J.; Bertagna, X.; Findling, J.; Shimatsu, A.; Gu, F.; Auchus, R.; Leelawattana, R.; Jig, L.E. Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study. In: Endocrine Abstracts; , 2019; 63, p. OC3.1.
[36]
Lamb, Y.N. Ozanimod: First approval. Drugs, 2020, 80(8), 841-848.
[http://dx.doi.org/10.1007/s40265-020-01319-7] [PMID: 32385738]
[37]
Elliott, W.; Chan, J. Ozanimod Capsules (Zeposia). Intern. Med. Alert., 2020, 42(9), 1.
[38]
Haarberg, S. Selumetinib (Koselugo™). Oncology Times, 2021, 43(23), 12.
[http://dx.doi.org/10.1097/01.COT.0000804752.58420.cf]
[39]
Markham, A.; Keam, S.J. Selumetinib: First approval. Drugs, 2020, 80(9), 931-937.
[http://dx.doi.org/10.1007/s40265-020-01331-x] [PMID: 32504375]
[40]
Zantout, S.; Tamer, M.D. Selumetinib (KOSELUGO, AstraZeneca). Available from: https://www.hoparx.org/drug-updates-from-the-fda/selumetinib-koselugo-astrazeneca (Accessed on: 27/01/2022).
[41]
Perkey, C. Tucatinib (Tukysa®). Oncol. Times, 2020, 42(24), 15-20.
[42]
Lee, A. Tucatinib: First approval. Drugs, 2020, 80(10), 1033-1038.
[http://dx.doi.org/10.1007/s40265-020-01340-w] [PMID: 32548668]
[43]
Fala, L. Pemazyre (Pemigatinib) first targeted therapy fda approved for cholangiocarcinoma with FGFR2 biomarker. CCANEWS, 2020, 1(1), 1.
[44]
Kabu, K.; Takei, S.; Kondo, M.; Kitazawa, K.; Harada, T. Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre® Tablets), a selective fibroblast growth factor receptor (FGFR) inhibitor. Nippon Yakurigaku Zasshi, 2021, 156(6), 392-402.
[http://dx.doi.org/10.1254/fpj.21087] [PMID: 34719574]
[45]
Mann, J.E. Pemigatinib (Pemazyre®). Oncology Times, 2020, 42(10), 14.
[http://dx.doi.org/10.1097/01.COT.0000668212.11555.13]
[46]
Hedgecorth, J. Sacituzumab Govitecan-Hziy (Trodelvy™). Oncol. Times, 2021, 43(8), 5-10.
[47]
Chaplin, S. Opicapone: Once-daily adjunctive therapy for Parkinson’s disease. Prescriber, 2017, 28(2), 55-56.
[http://dx.doi.org/10.1002/psb.1543]
[48]
OPICAPONE (Ongentys®▼) for Parkinson’s Disease. Available from: https://www.panmerseyapc.nhs.uk/media/2281/opicapone_parkinsons.pdf (Accessed on: 27/01/2022).
[49]
Sproat, M.; Mann, J.E. Capmatinib (Tabrecta™). Oncol. Times, 2021, 43(6), 14-41.
[50]
Dhillon, S. Capmatinib: First approval. Drugs, 2020, 80(11), 1125-1131.
[http://dx.doi.org/10.1007/s40265-020-01347-3] [PMID: 32557339]
[51]
Fala, L. Tabrecta (Capmatinib) approved for patients with metastatic NSCLC and MET Exon 14 skipping mutation; Oncol Drug Coding Update, 2021.
[52]
Markham, A. Selpercatinib: First approval. Drugs, 2020, 80(11), 1119-1124.
[http://dx.doi.org/10.1007/s40265-020-01343-7] [PMID: 32557397]
[53]
Elliott, W.; Chan, J. Selpercatinib capsules (Retevmo). Intern. Med. Alert., 2020, 42(12), 1.
[54]
Retevmo (selpercatinib). Available from: https://www.drugs.com/history/retevmo.html (Accessed on: 15/02/2022).
[55]
Dhillon, S. Ripretinib: First approval. Drugs, 2020, 80(11), 1133-1138.
[http://dx.doi.org/10.1007/s40265-020-01348-2] [PMID: 32578014]
[56]
Haarberg, S. Ripretinib (Qinlock™). Oncology Times, 2020, 42(16), 18.
[http://dx.doi.org/10.1097/01.COT.0000696436.82268.ff]
[57]
Ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.). Available from: https://www.hoparx.org/drug-updates-from-the-fda/ripretinib-qinlock-deciphera-pharmaceuticals-llc (Accessed on: 15/02/2022).
[58]
Barradell, L.B.; Fitton, A. Artesunate. Drugs, 1995, 50(4), 714-741.
[http://dx.doi.org/10.2165/00003495-199550040-00009] [PMID: 8536555]
[59]
Efferth, T.; Dunstan, H.; Sauerbrey, A.; Miyachi, H.; Chitambar, C. The anti-malarial artesunate is also active against cancer. Int. J. Oncol., 2001, 18(4), 767-773.
[http://dx.doi.org/10.3892/ijo.18.4.767] [PMID: 11251172]
[60]
Efferth, T.; Romero, M.R.; Wolf, D.G.; Stamminger, T.; Marin, J.J.G.; Marschall, M. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis., 2008, 47(6), 804-811.
[http://dx.doi.org/10.1086/591195] [PMID: 18699744]
[61]
Frampton, J.E. Inebilizumab: First approval. Drugs, 2020, 80(12), 1259-1264.
[http://dx.doi.org/10.1007/s40265-020-01370-4] [PMID: 32729016]
[62]
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD). 2021. Available from: https://www.businesswire.com/news/home/20211004005304/en/Ne
[63]
Markham, A. Lurbinectedin: First approval. Drugs, 2020, 80(13), 1345-1353.
[http://dx.doi.org/10.1007/s40265-020-01374-0] [PMID: 32816202]
[64]
Mann, J.E. Lurbinectedin (Zepzelca™). Oncology Times, 2020, 42(18), 18.
[http://dx.doi.org/10.1097/01.COT.0000717736.88965.e9]
[65]
Rajput, P.S.; Khan, S.R.; Singh, P.; Chawla, P.A. Treatment of small cell lung cancer with lurbinectedin: A review. Anticancer. Agents Med. Chem., 2022, 22(5), 812-820.
[http://dx.doi.org/10.2174/1871520621666210706150057] [PMID: 34229593]
[66]
Shirley, M. Triheptanoin: First approval. Drugs, 2020, 80(15), 1595-1600.
[http://dx.doi.org/10.1007/s40265-020-01399-5] [PMID: 32897506]
[67]
Kim, E.S.; Keam, S.J. Triheptanoin in the management of long-chain fatty acid oxidation disorders: A profile of its use. Drugs Ther. Perspect., 2021, 37(5), 187-193.
[http://dx.doi.org/10.1007/s40267-021-00816-3]
[68]
Gillingham, M.B.; Heitner, S.B.; Martin, J.; Rose, S.; Goldstein, A.; El-Gharbawy, A.H.; Deward, S.; Lasarev, M.R.; Pollaro, J.; DeLany, J.P.; Burchill, L.J.; Goodpaster, B.; Shoemaker, J.; Matern, D.; Harding, C.O.; Vockley, J. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: A double blinded, randomized controlled trial. J. Inherit. Metab. Dis., 2017, 40(6), 831-843.
[http://dx.doi.org/10.1007/s10545-017-0085-8] [PMID: 28871440]
[69]
Vockley, J.; Burton, B.; Berry, G.T.; Longo, N.; Phillips, J.; Sanchez-Valle, A.; Tanpaiboon, P.; Grunewald, S.; Murphy, E.; Bowden, A.; Chen, W.; Chen, C.Y.; Cataldo, J.; Marsden, D.; Kakkis, E. Results from a 78‐week, single‐arm, open‐label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long‐chain fatty acid oxidation disorders (LC‐FAOD). J. Inherit. Metab. Dis., 2019, 42(1), 169-177.
[http://dx.doi.org/10.1002/jimd.12038] [PMID: 30740733]
[70]
Keam, S.J. Remimazolam: First approval. Drugs, 2020, 80(6), 625-633.
[http://dx.doi.org/10.1007/s40265-020-01299-8] [PMID: 32274703]
[71]
Markham, A. Fostemsavir: First approval. Drugs, 2020, 80(14), 1485-1490.
[http://dx.doi.org/10.1007/s40265-020-01386-w] [PMID: 32852743]
[72]
Elliott, W.; Chan, J. Fostemsavir extended-release tablets (Rukobia). Intern. Med. Alert., 2020, 42(15), 1.
[73]
Lovell, A. Decitabine/Cedazuridine (Inqovi®). Oncology Times, 2021, 43(2), 15.
[http://dx.doi.org/10.1097/01.COT.0000732984.08830.cd]
[74]
Dhillon, S. Decitabine/cedazuridine: First approval. Drugs, 2020, 80(13), 1373-1378.
[http://dx.doi.org/10.1007/s40265-020-01389-7] [PMID: 32860582]
[75]
Quattlebaum, H. Decitabine and Cedazuridine (INQOVI, Astex Pharmaceuticals, Inc.) with PAP. Available from: https://www.hoparx.org/drug-updates-from-the-fda/decitabine-and-cedazuridine-inqovi-astex-pharmaceuticals-inc (Accessed on 15/02/2022).
[76]
Woods, A.D.; Porter, C.L.; Feldman, S.R. Abametapir for the treatment of head lice: A drug review. Ann. Pharmacother., 2022, 56(3), 352-357.
[http://dx.doi.org/10.1177/10600280211027968] [PMID: 34157881]
[77]
Bowles, V.M.; Yoon, K.S.; Barker, S.C.; Tran, C.; Rhodes, C.; Clark, M.J. Ovicidal efficacy of abametapir against eggs of human head and body lice (Anoplura: Pediculidae). J. Med. Entomol., 2017, 54(1), 167-172.
[http://dx.doi.org/10.1093/jme/tjw132] [PMID: 28082644]
[78]
Butler, S. Tafasitamab-cxis (Monjuvi®). Oncology Times, 2020, 42(22), 22.
[http://dx.doi.org/10.1097/01.COT.0000723636.68056.b8]
[79]
Hoy, S.M. Tafasitamab: First approval. Drugs, 2020, 80(16), 1731-1737.
[http://dx.doi.org/10.1007/s40265-020-01405-w] [PMID: 32946059]
[80]
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a Firstline Treatment for Diffuse Large B-Cell Lymphoma. 2021. Available from: https://www.morphosys.com/index.php/en/news/morphosys-and-incyte-announce-first-patient-dosed-phase-3-frontmind-study-evaluating (Accessed on: 15/02/2022).
[81]
Minor, C. Belantamab Mafodotin-Blmf (Blenrep). Oncology Times, 2021, 43(4), 15.
[http://dx.doi.org/10.1097/01.COT.0000735044.64635.0e]
[82]
Markham, A. Belantamab mafodotin: First approval. Drugs, 2020, 80(15), 1607-1613.
[http://dx.doi.org/10.1007/s40265-020-01404-x] [PMID: 32936437]
[83]
Constantiner, M.; Snyder, C. Blenrep® for relapsed or refractory multiple myeloma.
[84]
Dhillon, S. Risdiplam: First approval. Drugs, 2020, 80(17), 1853-1858.
[http://dx.doi.org/10.1007/s40265-020-01410-z] [PMID: 33044711]
[85]
Aschenbrenner, D.S. First oral drug approved for spinal muscular atrophy. Am. J. Nurs., 2020, 120(12), 22-23.
[http://dx.doi.org/10.1097/01.NAJ.0000724220.73804.9d] [PMID: 33214367]
[86]
Collins, F.; Plough, S. FDA clears first drug for premature aging disease. Nat. Biotechnol., 2021, 39(1), 7.
[http://dx.doi.org/10.1038/s41587-020-00802-6] [PMID: 33432221]
[87]
Markham, A. Oliceridine: First approval. Drugs, 2020, 80(16), 1739-1744.
[http://dx.doi.org/10.1007/s40265-020-01414-9] [PMID: 33025536]
[88]
Elliott, W.; Chan, J. Oliceridine Injection (Olinvyk). Intern. Med. Alert., 2020, 42(17), 1.
[89]
Azzam, A.A.H.; Lambert, D.G. Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain. Expert Opin. Drug Discov., 2022, 17(3), 215-223.
[http://dx.doi.org/10.1080/17460441.2022.2008903] [PMID: 34817313]
[90]
Dhillon, S. Viltolarsen: First approval. Drugs, 2020, 80(10), 1027-1031.
[http://dx.doi.org/10.1007/s40265-020-01339-3] [PMID: 32519222]
[91]
Eleswarpu, S.S.; Habib, A.S. Oliceridine in the treatment of moderate to severe acute pain. Pain Manag., 2021, 11(3), 237-248.
[http://dx.doi.org/10.2217/pmt-2020-0087] [PMID: 33455450]
[92]
Heo, Y.A. Satralizumab: First approval. Drugs, 2020, 80(14), 1477-1482.
[http://dx.doi.org/10.1007/s40265-020-01380-2] [PMID: 32797372]
[93]
Voelker, R. Therapy approved for rare neurological autoimmune disorder. JAMA, 2020, 324(13), 1277-1277.
[http://dx.doi.org/10.1001/jama.2020.18725] [PMID: 33021656]
[94]
Dhillon, S. Clascoterone: First approval. Drugs, 2020, 80(16), 1745-1750.
[http://dx.doi.org/10.1007/s40265-020-01417-6] [PMID: 33030710]
[95]
Kim, E.S.; Keam, S.J. Clascoterone 1% cream in acne vulgaris: A profile of its use. Drugs Ther. Perspect., 2021, 37(5), 194-198.
[http://dx.doi.org/10.1007/s40267-021-00831-4]
[96]
Markham, A. Pralsetinib: First approval. Drugs, 2020, 80(17), 1865-1870.
[http://dx.doi.org/10.1007/s40265-020-01427-4] [PMID: 33136236]
[97]
Elliott, W.; Chan, J. Pralsetinib Capsules (Gavreto). Intern. Med. Alert., 2020, 42(20), 1.
[98]
Saxena, D.; Kaul, G.; Dasgupta, A.; Chopra, S. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today, 2021, 57(8), 483-490.
[http://dx.doi.org/10.1358/dot.2021.57.8.3280599] [PMID: 34405205]
[99]
Mullard, A. FDA approves antibody cocktail for Ebola virus. Nat. Rev. Drug Discov., 2020, 19(12), 827-828.
[http://dx.doi.org/10.1038/d41573-020-00197-8] [PMID: 33144717]
[100]
Aleem, A.; Kothadia, J.P. Remdesivir. In: StatPearls; Publishing: Treasure Island (FL), 2022.
[101]
Odeti, S.; Yellepeddi, V.K. Remdesivir (Veklury) for the treatment of COVID-19 in hospitalized patients. Am. Fam. Physician, 2021, 104(3), 311-312.
[PMID: 34523893]
[102]
Dhillon, S. Lonafarnib: First approval. Drugs, 2021, 81(2), 283-289.
[http://dx.doi.org/10.1007/s40265-020-01464-z] [PMID: 33590450]
[103]
Voelker, R. First progeria drug is approved. JAMA, 2021, 325(1), 20-20.
[PMID: 33399831]
[104]
Scott, L.J.; Keam, S.J. Lumasiran: First approval. Drugs, 2021, 81(2), 277-282.
[http://dx.doi.org/10.1007/s40265-020-01463-0] [PMID: 33405070]
[105]
Hulton, S.A. Lumasiran: Expanding the treatment options for patients with primary hyperoxaluria type 1. Expert Opin. Orphan Drugs, 2021, 9(7-10), 189-198.
[http://dx.doi.org/10.1080/21678707.2021.2003779]
[106]
Garrelfs, S.; Frishberg, Y.; Hulton, S.; Koren, M.; O’Riordan, W.; Cochat, P.; Deschenes, G.; Shasha-Lavsky, H.; Saland, J.; Van’t Hoff, W.; Fuster, D.G.; Magen, D.; Moochhala, S.; Schalk, G.; Simkova, E.; Groothoff, J.; Sas, D.; Meliambro, K.; Lu, J.; Garg, P.; Gansner, J.; McGregor, T.; Lieske, J. Illuminate A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1). Nephrol. Dial. Transplant., 2020, 35(S3), gfaa146.LB002.
[http://dx.doi.org/10.1093/ndt/gfaa146.LB002]
[107]
Markham, A. Setmelanotide: First approval. Drugs, 2021, 81(3), 397-403.
[http://dx.doi.org/10.1007/s40265-021-01470-9] [PMID: 33638809]
[108]
Rickmann, M. Naxitamab. Humanized anti-GD2 ganglioside monoclonal antibody, Treatment of high-risk neuroblastoma. Drugs Future, 2021, 46(3), 197-205.
[http://dx.doi.org/10.1358/dof.2021.46.3.3223919]
[109]
Markham, A. Naxitamab: First approval. Drugs, 2021, 81(2), 291-296.
[http://dx.doi.org/10.1007/s40265-021-01467-4] [PMID: 33616889]
[110]
Cai, H.H. Therapeutic monoclonal antibodies approved by FDA in 2020. Clin. Res. Immunol., 2021, 4, 1-2.
[111]
Lee, A. Berotralstat: First approval. Drugs, 2021, 81(3), 405-409.
[http://dx.doi.org/10.1007/s40265-021-01475-4] [PMID: 33646555]
[112]
Lundbeck announces European Medicines Agency acceptance of marketing authorization application for eptinezumab for the prevention of migraine. Available from: https://news.cision.com/h--lundbeck-a-s/r/lundbeck-announces-european-medicines-agency-acceptance-of-marketing-authorization-application-for-e,c3260817
[113]
Powell, J.; Piszczatoski, C.; Rubido, E. Orladeyo (Berotralstat): A novel oral therapy for the prevention of hereditary angioedema. Ann. Pharmacother., 2022, 56(4), 488-493.
[http://dx.doi.org/10.1177/10600280211032982] [PMID: 34282650]
[114]
Geer, K. Tirbanibulin (Klisyri) for the Treatment of Actinic Keratosis. Am. Fam. Physician, 2021, 104(5), 519-520.
[PMID: 34783508]
[115]
Elliott, W.; Chan, J. Tirbanibulin ointment (Klisyri). Intern. Med. Alert., 2021, 43(2), 1.
[116]
Exton, P. Almirall US Launches Klisyri®(tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis. 2021. Available from: https://almirall.us/pdf/AlmirallUS-KlisyriLaunchPR_2021Feb18.pdf (Accessed on: 03/03/2022).
[117]
Markham, A. Margetuximab: First approval. Drugs, 2021, 81(5), 599-604.
[http://dx.doi.org/10.1007/s40265-021-01485-2] [PMID: 33761116]
[118]
Schott, A. Systemic treatment for HER2-positive metastatic breast cancer. Recuperado el., 2015, 15, 1-150.
[119]
Rugo, H.S. Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs. trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584.
[http://dx.doi.org/10.1001/jamaoncol.2020.7932] [PMID: 33480963]
[120]
Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol. Res., 2021, 165, 105463.
[http://dx.doi.org/10.1016/j.phrs.2021.105463] [PMID: 33513356]
[121]
Skidmore-Roth, L. Mosby’s 2021 Nursing Drug Reference E-Book; Elsevier Health Sciences: London, 2020.
[122]
Imran, M.; Asdaq, S.M.B.; Khan, S.A.; Unnikrishnan Meenakshi, D.; Alamri, A.S.; Alsanie, W.F.; Alhomrani, M.; Mohzari, Y.; Alrashed, A.; AlMotairi, M.; Alkhaldi, E.H.; Alorabi, A.K.; Alshrari, A.S.; Tauseef, M. Abida; Alaqel, S.I.; Alam, O.; Bakht, M.A. Innovations and patent trends in the development of USFDA approved protein kinase inhibitors in the last two decades. Pharmaceuticals, 2021, 14(8), 710.
[http://dx.doi.org/10.3390/ph14080710] [PMID: 34451807]
[123]
Elliott, W.; Chan, J. Vericiguat tablets (Verquvo). Intern. Med. Alert., 2021, 43(5), 1.
[124]
Markham, A.; Duggan, S. Vericiguat: First approval. Drugs, 2021, 81(6), 721-726.
[http://dx.doi.org/10.1007/s40265-021-01496-z] [PMID: 33770393]
[125]
Brand Name: Verquvo Generic Name: Vericiguat Manufacturer1: Merck & Co, Inc. Available from: https://pharmacy.wvu.edu/media/3366/verquvo-vericiguat-monograph.pdf (Accessed on 03/03/2022).
[126]
Michienzi, S.M. Cabenuva: A Novel Long-Acting Injectable HIV Treatment. IDSE, 2021. Available from: https://www.idse.net/Article/PrintArticle?ArticleId=63827 (Accessed on: 25/02/2022).
[127]
Elliott, W.; Chan, J. Cabotegravir extended-release and rilpivirine injectable suspension (Cabenuva) and cabotegravir tablets (Vocabria). Intern. Med. Alert., 2021, 43(4), 1.
[128]
Heo, Y.A. Voclosporin: First approval. Drugs, 2021, 81(5), 605-610.
[http://dx.doi.org/10.1007/s40265-021-01488-z] [PMID: 33788181]
[129]
Warning, B. Vericiguat. Am. J. Health Syst. Pharm., 2021, 78(12), 1021-1023.
[http://dx.doi.org/10.1093/ajhp/zxab118] [PMID: 33880493]
[130]
Kaufman, M.B. FDA Approves Belimumab & Voclosporin for Lupus Nephritis. Available from: The-rheumatologist.org/article/fda-approves-belimumab-voclosporin-for-lupus-nephritis/3/ (Accessed on: 25/02/2022).
[131]
Markham, A. Tepotinib: First approval. Drugs, 2020, 80(8), 829-833.
[http://dx.doi.org/10.1007/s40265-020-01317-9] [PMID: 32361823]
[132]
Yamazaki, K.; Ryoo, B.Y.; Doi, T.; Paik, P.K.; Veillon, R.; Decaens, T.; Faivre, S.; Falchook, G.S.; Hong, D.S.; Scheele, J.; Bruns, R.; Berghoff, K.; Qin, S. Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours. Ann. Oncol., 2019, 30, ix26.
[http://dx.doi.org/10.1093/annonc/mdz420.006]
[133]
Lovell, A. Umbralisib (Ukoniq™). Oncology Times, 2021, 43(21), 13.
[http://dx.doi.org/10.1097/01.COT.0000800784.70238.35]
[134]
Dhillon, S.; Keam, S.J. Umbralisib: First approval. Drugs, 2021, 81(7), 857-866.
[http://dx.doi.org/10.1007/s40265-021-01504-2] [PMID: 33797740]
[135]
Tosylate, U. Umbralisib tosylate. Am. J. Health Syst. Pharm., 2021, 78(12), 1018-1020.
[http://dx.doi.org/10.1093/ajhp/zxab117] [PMID: 33880512]
[136]
Markham, A. Evinacumab: First approval. Drugs, 2021, 81(9), 1101-1105.
[http://dx.doi.org/10.1007/s40265-021-01516-y] [PMID: 34003472]
[137]
Elliott, W.; Chan, J. Evinacumab-dgnb Injection (Evkeeza). Intern Med Alert, 2021, 43(6)
[138]
Warden, B.A.; Duell, P.B. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev. Cardiovasc. Ther., 2021, 19(8), 739-751.
[http://dx.doi.org/10.1080/14779072.2021.1955349] [PMID: 34253139]
[139]
Dhillon, S. Trilaciclib: First approval. Drugs, 2021, 81(7), 867-874.
[http://dx.doi.org/10.1007/s40265-021-01508-y] [PMID: 33861388]
[140]
Stevens, A.; O’Shaughnessy, J.; Cao, S.; Sorrentino, J.; Horton, J.; Yi, J.; Tan, A. 339 Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy. J. Immunother. Cancer, 2021, 9(2)(Suppl. 2), A365.
[http://dx.doi.org/10.1136/jitc-2021-SITC2021.339]
[141]
Shirley, M. Casimersen: First approval. Drugs, 2021, 81(7), 875-879.
[http://dx.doi.org/10.1007/s40265-021-01512-2] [PMID: 33861387]
[142]
Wagner, K.R.; Kuntz, N.L.; Koenig, E.; East, L.; Upadhyay, S.; Han, B.; Shieh, P.B. Safety, tolerability, and pharmacokinetics of casimersen in patients with D uchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial. Muscle Nerve, 2021, 64(3), 285-292.
[http://dx.doi.org/10.1002/mus.27347] [PMID: 34105177]
[143]
Kang, C. Fosdenopterin: First approval. Drugs, 2021, 81(8), 953-956.
[http://dx.doi.org/10.1007/s40265-021-01520-2] [PMID: 33909276]
[144]
Hydrobromide, F. AHFS® first Release™. 2021, 78(14), 1275-1276.
[145]
Dhillon, S. Melphalan Flufenamide (Melflufen): First approval. Drugs, 2021, 81(8), 963-969.
[http://dx.doi.org/10.1007/s40265-021-01522-0] [PMID: 33961277]
[146]
Lindberg, J.; Nilvebrant, J.; Nygren, P.Å.; Lehmann, F. Progress and future directions with peptide-drug conjugates for targeted cancer therapy. Molecules, 2021, 26(19), 6042.
[http://dx.doi.org/10.3390/molecules26196042] [PMID: 34641586]
[147]
Richardson, P.G.; Oriol, A.; Larocca, A.; Bladé, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Nadeem, O.; Hiemenz, J.W.; Hassoun, H.; Touzeau, C.; Alegre, A.; Paner, A.; Maisel, C.; Mazumder, A.; Raptis, A.; Moreb, J.S.; Anderson, K.C.; Laubach, J.P.; Thuresson, S.; Thuresson, M.; Byrne, C.; Harmenberg, J.; Bakker, N.A.; Mateos, M.V. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J. Clin. Oncol., 2021, 39(7), 757-767.
[http://dx.doi.org/10.1200/JCO.20.02259] [PMID: 33296242]
[148]
Sproat, M. Tivozanib (Fotivda®). Oncol. Times, 2021, 43(16), 14-20.
[149]
Markham, A. Ponesimod: First approval. Drugs, 2021, 81(8), 957-962.
[http://dx.doi.org/10.1007/s40265-021-01523-z] [PMID: 33939119]
[150]
Blair, H.A. Dasiglucagon: First approval. Drugs, 2021, 81(9), 1115-1120.
[http://dx.doi.org/10.1007/s40265-021-01531-z] [PMID: 34047955]
[151]
Elliott, W.; Chan, J. Viloxazine Extended-release capsules (Qelbree). Intern. Med. Alert., 2021, 43(9), 1.
[152]
Elliott, W.; Chan, J. Drospirenone and estetrol tablets (Nextstellis). Intern. Med. Alert., 2021, 43(10), 1.
[153]
DeRuiter, J.; Holston, P.L. Drospirenone and estetrol (Nextstellis, Mayne Pharma). US Pharm., 2021, 46(10), 28-40.
[154]
Markham, A. Dostarlimab: First approval. Drugs, 2021, 81(10), 1213-1219.
[http://dx.doi.org/10.1007/s40265-021-01539-5] [PMID: 34106455]
[155]
Patnaik, A.; Weiss, G.J.; Rasco, D.W.; Blaydorn, L.; Mirabella, A.; Beeram, M.; Guo, W.; Lu, S.; Danaee, H.; McEachern, K.; Im, E.; Sachdev, J.C. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: A dose–escalation phase 1 trial. Cancer Chemother. Pharmacol., 2022, 89(1), 93-103.
[http://dx.doi.org/10.1007/s00280-021-04358-3] [PMID: 34750637]
[156]
Fala, L. Jemperli (Dostarlimab) first immunotherapy approved for recurrent or advanced mismatch repair-deficient endometrial cancer. Am. Health Drug Benefits, 2021, 14, 3179.
[157]
Elliott, W.; Chan, J. Pegcetacoplan Injection (Empaveli). Intern. Med. Alert., 2021, 43(12), 1.
[158]
Syed, Y.Y. Amivantamab: First approval. Drugs, 2021, 81(11), 1349-1353.
[http://dx.doi.org/10.1007/s40265-021-01561-7] [PMID: 34292533]
[159]
Parums, D.V. Editorial: global regulatory initiatives deliver accelerated approval of the first bispecific therapeutic monoclonal antibody for advanced Non-Small Cell Lung Cancer (NSCLC). Med. Sci. Monit., 2021, 27, e934854.
[http://dx.doi.org/10.12659/MSM.934854] [PMID: 34565792]
[160]
Keam, S.J. Piflufolastat F 18. Diagnostic First Approval. Mol. Diagn. Ther., 2021, 25(5), 647-656.
[http://dx.doi.org/10.1007/s40291-021-00548-0] [PMID: 34292532]
[161]
Mid-Year Review: New Drug Approvals By Patricia Van Arnum. Available from: https://www.dcatvci.org/features/mid-year-review-new-drug-approvals/
[162]
Blair, H.A. Sotorasib: First approval. Drugs, 2021, 81(13), 1573-1579.
[http://dx.doi.org/10.1007/s40265-021-01574-2] [PMID: 34357500]
[163]
Mann, J.E. Sotorasib (Lumakras™). Oncol. Times, 2021, 43(15), 12-17.
[164]
Expertini. Available from: https://expertini.com/news/world/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-gc-mutated-colorectal-cancer/16/09/2021/
[165]
Kang, C. Infigratinib: First approval. Drugs, 2021, 81(11), 1355-1360.
[http://dx.doi.org/10.1007/s40265-021-01567-1] [PMID: 34279850]
[166]
Fala, L. Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations. J. Hematol. Oncol. Pharm., 2021, 11(4), 1.
[167]
Paik, J. Olanzapine/Samidorphan: First approval. Drugs, 2021, 81(12), 1431-1436.
[http://dx.doi.org/10.1007/s40265-021-01568-0] [PMID: 34304374]
[168]
Sun, L.; von Moltke, L.; Rowland Yeo, K. Application of physiologically based pharmacokinetic modeling to predict the effect of renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination. Clin. Pharmacokinet., 2021, 60(5), 637-647.
[http://dx.doi.org/10.1007/s40262-020-00969-w] [PMID: 33313995]
[169]
Brunette, M.F.; Correll, C.U.; Stephanie, S.; McDonnell, D.; DiPetrillo, L.; Jiang, Y.; Simmons, A.; Silverman, B.L.; Citrome, L.; Green, A.I. Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: A phase 2, randomized clinical trial. J. Clin. Psychiatry, 2020, 81(2)
[170]
Lee, A. Ibrexafungerp: First approval. Drugs, 2021, 81(12), 1445-1450.
[http://dx.doi.org/10.1007/s40265-021-01571-5] [PMID: 34313977]
[171]
Elliott, W.; Chan, J. Ibrexafungerp Tablets (Brexafemme). Intern. Med. Alert., 2021, 43(15), 1.
[172]
Sobel, R.; Nyirjesy, P.; Ghannoum, M.A.; Delchev, D.A.; Azie, N.E.; Angulo, D.; Harriott, I.A.; Borroto-Esoda, K.; Sobel, J.D. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: A global phase 3, randomised, placebo‐controlled superiority study (VANISH 306). BJOG, 2022, 129(3), 412-420.
[http://dx.doi.org/10.1111/1471-0528.16972] [PMID: 34676663]
[173]
Frampton, J.E. Finerenone: First approval. Drugs, 2021, 81(15), 1787-1794.
[http://dx.doi.org/10.1007/s40265-021-01599-7] [PMID: 34519996]
[174]
Elliott, W.; Chan, J. Finerenone tablets (Kerendia). Intern. Med. Alert., 2021, 43(16), 1.
[175]
Bahia, M.T.; Andrade, I.M.; Martins, T.A.F.; Nascimento, Á.F.S.; Diniz, L.F.; Caldas, I.S.; Talvani, A.; Trunz, B.B.; Torreele, E.; Ribeiro, I. Fexinidazole: A potential new drug candidate for Chagas disease. PLoS Negl. Trop. Dis., 2012, 6(11), e1870.
[http://dx.doi.org/10.1371/journal.pntd.0001870] [PMID: 23133682]
[176]
Deeks, E.D. Fexinidazole: First global approval. Drugs, 2019, 79(2), 215-220.
[http://dx.doi.org/10.1007/s40265-019-1051-6] [PMID: 30635838]
[177]
Blair, H.A. Belumosudil: First approval. Drugs, 2021, 81(14), 1677-1682.
[http://dx.doi.org/10.1007/s40265-021-01593-z] [PMID: 34463931]
[178]
Deeks, E.D. Odevixibat: First approval. Drugs, 2021, 81(15), 1781-1786.
[http://dx.doi.org/10.1007/s40265-021-01594-y] [PMID: 34499340]
[179]
Deeks, E.D. Belzutifan: First approval. Drugs, 2021, 81(16), 1921-1927.
[http://dx.doi.org/10.1007/s40265-021-01606-x] [PMID: 34613603]
[180]
Deeks, E.D. Difelikefalin: First approval. Drugs, 2021, 81(16), 1937-1944.
[http://dx.doi.org/10.1007/s40265-021-01619-6] [PMID: 34674115]
[181]
Markham, A. Mobocertinib: First approval. Drugs, 2021, 81(17), 2069-2074.
[http://dx.doi.org/10.1007/s40265-021-01632-9] [PMID: 34716908]
[182]
Mann, J.E. Mobocertinib (Exkivity™). Oncology Times, 2022, 44(2), 11-12.
[http://dx.doi.org/10.1097/01.COT.0000818660.49005.83]
[183]
Markham, A. Tisotumab Vedotin: First approval. Drugs, 2021, 81(18), 2141-2147.
[http://dx.doi.org/10.1007/s40265-021-01633-8] [PMID: 34748188]
[184]
Aschenbrenner, D.S. New drug treats cervical cancer. Am. J. Nurs., 2022, 122(1), 21-21.
[http://dx.doi.org/10.1097/01.NAJ.0000815420.91630.18] [PMID: 34941590]
[185]
Deeks, E.D. Atogepant: First approval. Drugs, 2022, 82(1), 65-70.
[http://dx.doi.org/10.1007/s40265-021-01644-5] [PMID: 34813050]
[186]
Elliott, W.; Chan, J. Atogepant tablets (Qulipta). Intern. Med. Alert., 2021, 43(21), 1.
[187]
Shirley, M. Maralixibat: First approval. Drugs, 2022, 82(1), 71-76.
[http://dx.doi.org/10.1007/s40265-021-01649-0] [PMID: 34813049]
[188]
Weight, P.; Dose, I.V. Prescribing information 1 indications and usage. Available from: https://yaorongyun-enterprise-data.oss-cn-shanghai.aliyuncs.com/FDA/4cfbbfbd5d7134a7ce131cbd0a9390cf_214662s000lbl.pdf (Accessed on: 25/02/2022).
[189]
Chloride, M. Maralixibat chloride. Am. J. Health Syst. Pharm., 2022, 79(3), 117-119.
[http://dx.doi.org/10.1093/ajhp/zxab417] [PMID: 34964823]
[190]
Lee, A. Avacopan: First approval. Drugs, 2022, 82(1), 79-85.
[http://dx.doi.org/10.1007/s40265-021-01643-6] [PMID: 34826105]
[191]
Deeks, E.D. Asciminib: First approval. Drugs, 2022, 82(2), 219-226.
[http://dx.doi.org/10.1007/s40265-021-01662-3] [PMID: 35041175]
[192]
Duggan, S. Vosoritide: First approval. Drugs, 2021, 81(17), 2057-2062.
[http://dx.doi.org/10.1007/s40265-021-01623-w] [PMID: 34694597]
[193]
Voelker, R. A Treatment Advance for Patients With Posttransplant CMV. JAMA, 2022, 327(1), 27-27.
[http://dx.doi.org/10.1001/jama.2021.23423] [PMID: 34982134]
[194]
Voelker, R. Lighting the way for improved detection of ovarian cancer. JAMA, 2022, 327(1), 27-27.
[http://dx.doi.org/10.1001/jama.2021.22960] [PMID: 34982136]
[195]
Richmond, K. FDA Approves TEZSPIRE™(TEZEPELUMABEKKO) in the us for severe asthma. Available from: https://www.easternprogress.com/fda-approves-tezspire-tezepelumab-ekko-in-the-u-s-for-severe-asthma/article_09530203-071d-50b6-9853-b013c15304ea.html (Accessed on: 21/11/2021).
[196]
Dolgin, E. FDA go-ahead for myasthenia gravis agent. Nat. Biotechnol., 2022, 40(1), 4.
[http://dx.doi.org/10.1038/s41587-021-01198-7] [PMID: 35043016]
[197]
Lamb, Y.N. Inclisiran: First approval. Drugs, 2021, 81(3), 389-395.
[http://dx.doi.org/10.1007/s40265-021-01473-6] [PMID: 33620677]
[198]
Elliott, W.; Chan, J. Inclisiran Injection (Leqvio). Intern. Med. Alert., 2022, 44(2), 1.
[199]
LEO Pharma announces FDA approval of Adbry™(tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. Available from: https://www.lelezard.com/en/news-20171948.html (Accessed on 25/02/2022).
[200]
Hewett, L. LEO Pharma announces FDA approval of Adbry™(tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. Available from: https://nationaleczema.org/blog/leo-122821/ (Accessed on: 25/02/2022).

Rights & Permissions Print Cite
Article Metrics
59
2
© 2024 Bentham Science Publishers | Privacy Policy